XML 46 R34.htm IDEA: XBRL DOCUMENT v3.19.2
BUSINESS COMBINATION AND DECONSOLIDATION OF SUBSIDIARY (Tables)
6 Months Ended
Jun. 30, 2019
Business Combination And Deconsolidation Of Subsidiary  
Purchase price of acquisition
    Shares     Amount  
Upfront Consideration Shares     5,700,000     $ 19,038,000  
Adjusted Contingent Shares     8,410,875       14,627,358  
Acquisition Warrant Shares     8,018,071       4,642  
Acquisition costs     -       399,942  
Total purchase price     22,128,946     $ 34,069,942  
Schedule of assets acquired and liabilities assumed

The following table summarizes the preliminary estimated fair values of the assets and liabilities assumed in the CHI acquisition, which is subject to change during measurement period:

 

Net assets acquired:      
Cash   $ 8,487,489  
Note receivable from CURE     2,000,000  
Property, plant and equipment     82,700  
Patents and development technology     650,000  
In-process research and development     14,460,000  
Goodwill     9,178,477  
Accounts payable     (353,856 )
Payroll tax liabilities     (834,810 )
Net assets acquired     33,670,000  
Acquisition costs     399,942  
Net assets acquired and acquisition costs incurred   $ 34,069,942  
Finite-Lived and Indefinite-Lived Intangible Assets Acquired

Information regarding identifiable intangible assets acquired in the CHI acquisition is presented below:

 

   

Weighted-average Estimated

useful life

  Preliminary Estimated Asset Fair Value  
Finite-lived intangible assets:          
Patent and developed technology   11.0 years   $ 650,000  
In-Process research and development   14.0 years     14,460,000  
Total finite-lived intangible assets acquired   14.0 years     15,110,000  
Schedule of business combination
    Three Months Ended June 30,     Six Months Ended June 30,  
    2019     2018     2019     2018  
Net revenues   $ 107,926     $ 407,588     $ 182,426     $ 838,774  
Net loss     (14,590,578       (2,344,350       (24,739,485       (4,200,631  
                                 
Net loss attributable to Cure per common share, basic   $ (0.36 )   $ (0.08 )   $ (0.67 )     (0.14  
Net loss attributable to Cure per common share, diluted     (0.36       (0.08       (0.67       (0.14  
Summary of Deconsolidation of Oak Therapeutics, Inc.

The following information summarizes the results of operations of Oak for the period January 1, 2019 through April 15, 2019, the date of deconsolidation:

 

    January 1, 2019 through April 15, 2019  
Revenue   $ -  
Net loss   $ 29,185